Moreover presence of insulin resistance and diabetes are risk factors for fibrosis progression and nonresponse to antiviral therapy in chronic hepatitis C (CHC).
外,胰岛素抵抗和糖尿病是慢性
型肝炎(CHC)中纤维化进展以及对抗病毒治疗无应答的危险因素。
Moreover presence of insulin resistance and diabetes are risk factors for fibrosis progression and nonresponse to antiviral therapy in chronic hepatitis C (CHC).
外,胰岛素抵抗和糖尿病是慢性
型肝炎(CHC)中纤维化进展以及对抗病毒治疗无应答的危险因素。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化的慢性肝(CHC)患者接受α干扰素包括派罗欣治疗时存在肝功能失代偿和死亡风险。
声明:以上例、词性分类均由互联网资源自
,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Moreover presence of insulin resistance and diabetes are risk factors for fibrosis progression and nonresponse to antiviral therapy in chronic hepatitis C (CHC).
此外,胰岛素抵抗糖尿病是慢性
型肝炎(CHC)中纤维化进
对抗病毒治疗无应答的危险因素。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化的慢性肝(CHC)患者接受α干扰素包括派罗欣治疗时存在肝功能失
死亡风险。
声明:上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不
表本软件的观点;若发现问题,欢迎向我们指正。
Moreover presence of insulin resistance and diabetes are risk factors for fibrosis progression and nonresponse to antiviral therapy in chronic hepatitis C (CHC).
此外,胰岛素抵抗和糖尿病型肝炎(CHC)中纤维化进展以及对抗病毒治疗无应答的危险因素。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化的肝(CHC)患者接受α干扰素包括派罗欣治疗时存在肝功能失代偿和死亡风险。
声明:以上例、词
分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Moreover presence of insulin resistance and diabetes are risk factors for fibrosis progression and nonresponse to antiviral therapy in chronic hepatitis C (CHC).
此外,胰岛素抵抗和糖尿病是慢性型肝炎(CHC)中纤维化进展以及对抗病毒治疗无应答的危险因素。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化的慢性肝(CHC)患者接受α干扰素包括派罗欣治疗时存在肝功能失代偿和死亡风险。
声明:以上例句、词性类均由互联网资源自动生成,部
过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Moreover presence of insulin resistance and diabetes are risk factors for fibrosis progression and nonresponse to antiviral therapy in chronic hepatitis C (CHC).
此外,胰岛素抵抗和糖尿病是慢性型肝炎(CHC)中纤维化进展以及对抗病毒治疗无应答的危险因素。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化的慢性肝(CHC)患者接受α干扰素包括派罗欣治疗时存在肝功能失代偿和死亡风险。
声明:以上例句、词性分类均由互联网资源自动生成,部分未工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Moreover presence of insulin resistance and diabetes are risk factors for fibrosis progression and nonresponse to antiviral therapy in chronic hepatitis C (CHC).
此外,胰岛素抵抗和糖尿病是慢性型肝炎(CHC)中纤维化进展以及对抗病毒治疗无应答的危险因素。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化的慢性肝(CHC)患者接受α干扰素包括派罗欣治疗时存在肝功能失代偿和死亡风险。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审,
达内容亦不代
本软件的观点;若发现问题,欢迎向我们指正。
Moreover presence of insulin resistance and diabetes are risk factors for fibrosis progression and nonresponse to antiviral therapy in chronic hepatitis C (CHC).
此外,胰岛素抵抗和糖尿病是慢性型肝炎(CHC)中纤维化进展以及对抗病毒治疗无应答的危险因素。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化的慢性肝(CHC)患者接受α干扰素包括派罗欣治疗时存在肝功能失代偿和死亡风险。
声明:以上、词性
类均由互联网资源自动生
,
未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Moreover presence of insulin resistance and diabetes are risk factors for fibrosis progression and nonresponse to antiviral therapy in chronic hepatitis C (CHC).
此外,胰岛素抵抗和糖尿病是性
型肝炎(CHC)中纤维
进展以及对抗病毒治疗无应答
危险因素。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬性
肝(CHC)
受α干扰素包括派罗欣治疗时存在肝功能失代偿和死亡风险。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件观点;若发现问题,欢迎向我们指正。
Moreover presence of insulin resistance and diabetes are risk factors for fibrosis progression and nonresponse to antiviral therapy in chronic hepatitis C (CHC).
此外,胰岛素抵抗和糖尿病是慢性型肝炎(CHC)中纤维化进展以及对抗病毒治疗无应答的危险因素。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化的慢性肝(CHC)患者接受α干扰素包括派罗欣治疗时存在肝功能失代偿和死亡风险。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,内容亦不代
本软件的观点;若发现问题,欢迎向我们指正。